Global Wet Age Related Macular Degeneration (AMD) Market Report, History and Forecast 2016-2027, Breakdown Data by Companies, Key Regions, Types and Application

Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.
Increased awareness among people about the condition has influenced the AMD treatment global demand. At the same time, the arrival of off-patent blockbuster drugs is reflecting favorably on the market particularly in third-world countries. This has allowed small-scale drug manufactures to penetrate untapped markets.

Market Analysis and Insights: Global Wet Age Related Macular Degeneration (AMD) Market
The research report studies the Wet Age Related Macular Degeneration (AMD) market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Wet Age Related Macular Degeneration (AMD) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

Global Wet Age Related Macular Degeneration (AMD) Scope and Segment
The global Wet Age Related Macular Degeneration (AMD) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Wet Age Related Macular Degeneration (AMD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.

Segment by Type
Wet Age-Related Macular Degeneration (Wet AMD)
Dry Age-Related Macular Degeneration (Dry AMD)

Segment by Age
Above 75 Years
Above 60 Years
Above 40 Years

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Novartis International (Switzerland)
Bayer (Germany)
Acucela (US)
Neurotech Pharmaceuticals (US)
Ophthotech (US)
GlaxoSmithKline (US)
Alimera Sciences (US)
StemCell (Canada)
F. Hoffmann-La Roche (Switzerland)
Regeneron Pharmaceutical (US)
Allergan (Ireland)
Adverum Biotechnologies (US)
Gilead Sciences (US)

Frequently Asked Questions